Pneumothorax Treatment Market to Reach USD 2.36 Billion by 2033 at 6.8% CAGR; North America Leads with 38.6% Share - Key Players: Pfizer, Medtronic, Teleflex

The global pneumothorax treatment market was valued at USD 1.48 billion in 2025 and is projected to reach nearly USD 2.36 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of respiratory disorders, rising incidence of traumatic chest injuries, and growing demand for minimally invasive thoracic treatment procedures. Expanding adoption of advanced chest drainage systems, portable suction devices, and image guided interventions is improving clinical outcomes and supporting market expansion globally. In addition, increasing healthcare infrastructure development, rising emergency care admissions, and growing awareness regarding early diagnosis and treatment of lung related complications are further contributing to market growth.

The market is also benefiting from continuous technological advancements in thoracic care devices, increasing regulatory approvals for innovative respiratory treatment solutions, and expanding investments in pulmonary healthcare services. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to support development of advanced respiratory and thoracic treatment technologies through streamlined approval pathways and safety regulations. Companies including Becton, Dickinson and Company, Teleflex Incorporated, Medtronic, and Cook Medical are actively focusing on innovative chest drainage products, minimally invasive pulmonary care solutions, and expanded market access initiatives to strengthen their global presence.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/pneumothorax-treatment-market?sai-v

Key Developments
February 2026: Rising adoption of minimally invasive thoracic drainage procedures across North America and Europe improved treatment outcomes and reduced hospitalization duration for pneumothorax patients. Major companies including Medtronic, Teleflex Incorporated, and Smiths Medical expanded advanced chest drainage and thoracic vent device portfolios.

January 2026: Increasing investments in emergency and critical care infrastructure across the United States, Germany, Japan, and China accelerated demand for advanced pneumothorax treatment devices and thoracic drainage systems. Healthcare providers focused on portable and AI-assisted monitoring technologies supporting real-time pleural pressure management.

December 2025: Growing prevalence of respiratory disorders, chest trauma, and post-surgical pneumothorax cases across Asia-Pacific strengthened adoption of minimally invasive catheter insertion and chest tube procedures. Abbott Laboratories and Vygon strengthened regional distribution networks and respiratory care technologies.

November 2025: Expansion of ambulatory surgical centers and trauma care facilities across Europe and North America increased utilization of compact thoracic vent devices and portable chest drainage systems. Hospitals increasingly focused on improving patient mobility and reducing procedure-related complications through advanced drainage technologies.

October 2025: Rising advancements in AI-enabled chest X-ray analysis and automated pneumothorax detection technologies improved diagnostic accuracy and emergency treatment planning globally. Research institutions in the United States developed deep-learning segmentation models supporting faster pneumothorax identification and radiology workflow optimization.

September 2025: Increasing collaborations between medical device manufacturers and healthcare institutions accelerated development of next-generation thoracic drainage systems with enhanced portability and safety features. Cook Medical and B. Braun Melsungen AG strengthened innovation strategies targeting minimally invasive respiratory care applications.

August 2025: Growing healthcare infrastructure modernization across India, Southeast Asia, and Middle East regions accelerated installation of advanced respiratory care and emergency treatment systems. Asia-Pacific emerged as the fastest growing regional market driven by increasing respiratory disease burden and expanding healthcare expenditure.

July 2025: Rising focus on portable and home-based respiratory monitoring technologies improved adoption of compact pneumothorax treatment devices across outpatient and ambulatory care settings globally. Companies explored digital monitoring solutions supporting remote patient management and real-time air leak assessment.

June 2025: Increasing government support for emergency healthcare infrastructure and growing awareness regarding early pneumothorax diagnosis supported strong growth in the global pneumothorax treatment market. North America maintained market leadership, while Asia-Pacific emerged as the fastest growing regional market due to rising trauma cases and healthcare investments.

Key Players
Pfizer Inc. | Fresenius Kabi USA | Akorn, Inc. | Piramal Critical Care | Baxter Healthcare Corporation | Valeant Pharmaceuticals North America LLC | Teva Pharmaceuticals USA, Inc. | Comed Chemicals Ltd. | UCB, Inc. | Midas Pharma GmbH | Others

Key Highlights
Pfizer Inc. - Holds a 16.2% share, driven by strong critical care pharmaceutical portfolio, advanced injectable drug development capabilities, and extensive global healthcare commercialization infrastructure.

Fresenius Kabi USA - Holds a 14.1% share, supported by hospital-focused injectable medicines, advanced infusion therapy solutions, and strong critical care manufacturing capabilities.

Akorn, Inc. - Holds an 11.8% share, fueled by specialty generic pharmaceutical production, sterile injectable manufacturing expertise, and broad acute care therapeutic offerings.

Piramal Critical Care - Holds a 10.0% share, driven by anesthesia and critical care treatment portfolio, advanced injectable drug manufacturing infrastructure, and expanding global healthcare partnerships.

Baxter Healthcare Corporation - Holds an 8.6% share, supported by intravenous therapy technologies, hospital care solutions, and strong sterile pharmaceutical delivery capabilities.

Valeant Pharmaceuticals North America LLC - Holds a 7.1% share, powered by specialty pharmaceutical commercialization expertise, acute care treatment offerings, and broad healthcare distribution networks.

Teva Pharmaceuticals USA, Inc. - Holds a 5.9% share, driven by extensive generic injectable portfolio, scalable pharmaceutical manufacturing infrastructure, and strong market accessibility initiatives.

Comed Chemicals Ltd. - Holds a 4.8% share, supported by active pharmaceutical ingredient manufacturing expertise, specialty chemical production capabilities, and growing pharmaceutical supply partnerships.

UCB, Inc. - Holds a 3.9% share, fueled by CNS-focused therapeutic innovation, advanced specialty pharmaceutical development, and expanding neurological treatment applications.

Midas Pharma GmbH - Holds a 3.0% share, driven by pharmaceutical sourcing expertise, API distribution infrastructure, and strong contract manufacturing support capabilities.

Others - Hold a combined 14.6% share, comprising regional injectable drug manufacturers, specialty pharmaceutical companies, and emerging critical care therapy developers advancing hospital-based treatment and acute care pharmaceutical solutions globally.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pneumothorax-treatment-market?sai-v

Market Drivers

Increasing incidence of traumatic injuries, chronic lung diseases, and spontaneous pneumothorax cases is significantly driving demand for pneumothorax treatment solutions globally.

Growing prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, and lung infections is accelerating expansion of the pneumothorax treatment market worldwide.

Rising adoption of minimally invasive thoracic procedures, chest drainage systems, pleurodesis therapies, and video-assisted thoracoscopic surgery (VATS) is strengthening market growth across healthcare systems.

Increasing awareness regarding early diagnosis and emergency respiratory care is improving treatment adoption and patient outcomes globally.

Expansion of healthcare infrastructure, trauma centers, pulmonary care units, and emergency medical services is contributing to higher utilization of pneumothorax treatment technologies.

Continuous advancements in thoracic imaging systems, AI-assisted diagnostics, portable drainage devices, and respiratory monitoring technologies are enhancing treatment precision and clinical efficiency.

Growing healthcare expenditure, government investments in emergency healthcare systems, and rising demand for advanced respiratory care solutions are further propelling market development worldwide.

Industry Developments

Rapid advancement in minimally invasive thoracic surgery techniques and digital chest drainage systems improving patient recovery time and treatment outcomes.

Increasing adoption of portable and smart chest drainage devices supporting enhanced monitoring and improved management of pneumothorax cases.

Growing investments in AI-powered respiratory imaging, robotic-assisted thoracic surgery, and advanced pulmonary diagnostics accelerating innovation in pneumothorax treatment.

Expansion of emergency respiratory care programs and telehealth-enabled pulmonary monitoring solutions improving access to specialized thoracic care services.

Rising collaborations among medical device manufacturers, hospitals, thoracic surgery centers, and research institutions driving development of advanced respiratory treatment technologies.

Strategic product launches and regulatory approvals for next-generation thoracic drainage systems and respiratory support devices supporting global market commercialization.

Continuous innovation in biocompatible pleural sealants, precision thoracic intervention tools, and wearable respiratory monitoring systems improving long-term patient management and clinical outcomes.

Regional Insights

North America 38.6% share: "Leads the market due to advanced healthcare infrastructure, strong adoption of minimally invasive thoracic procedures, increasing prevalence of respiratory diseases, and high investments in emergency pulmonary care technologies."

Europe 28.8% share: "Growth supported by expanding respiratory healthcare services, favorable reimbursement systems, rising awareness regarding thoracic disorders, and increasing adoption of advanced surgical technologies."

Asia Pacific 24.5% share: "Fastest-growing region driven by improving healthcare infrastructure, rising respiratory disease burden, increasing trauma cases, and expanding pulmonary care investments in countries such as China, India, Japan, and South Korea."

Latin America 4.2% share: "Emerging growth supported by improving emergency healthcare services, increasing awareness regarding respiratory disorders, and gradual modernization of thoracic care facilities."

Middle East & Africa 3.9% share: "Gradual growth driven by expanding hospital infrastructure, rising investments in respiratory care technologies, and improving access to advanced thoracic treatment services."

Speak to our analyst and get customization in the report as per your requirements:https://www.datamintelligence.com/customize/pneumothorax-treatment-market?sai-v

Key Segments
➥ By Medication

Local Anesthetics: Represents a significant segment, driven by increasing utilization during chest tube insertion, pleural procedures, and minimally invasive pneumothorax treatments.

Benzodiazepines: Represents a growing segment, fueled by increasing administration for anxiety relief and sedation during emergency respiratory procedures.

Antibiotics: Represents a substantial segment, driven by rising need to prevent or manage secondary infections associated with thoracic interventions and hospitalized patients.

Others: Represents an emerging segment, supported by ongoing development of advanced respiratory therapies, anti-inflammatory medications, and supportive pulmonary care solutions.

➥ By Treatment Type

Pleurectomy: Represents a significant segment, driven by increasing adoption in recurrent pneumothorax cases to reduce recurrence risk and improve long-term patient outcomes.

Bullectomy: Represents a growing segment, supported by rising prevalence of lung bullae-related spontaneous pneumothorax and advancements in thoracoscopic surgical procedures.

Pleurodesis: Represents the dominant segment, fueled by widespread utilization for preventing recurrent pneumothorax through pleural space adhesion techniques.

Others: Represents a moderate segment, driven by increasing use of chest drainage systems, video-assisted thoracoscopic surgery (VATS), and minimally invasive respiratory interventions.

➥ By Indication

Primary Spontaneous Pneumothorax Infection: Represents the dominant segment, driven by increasing incidence among young adults and growing awareness regarding early respiratory intervention.

Secondary Spontaneous Pneumothorax Infection: Represents a significant segment, supported by rising prevalence of chronic lung diseases such as COPD and pulmonary fibrosis.

Injury-related Pneumothorax Infection: Represents a growing segment, fueled by increasing trauma cases, road accidents, and sports-related thoracic injuries.

Tension Pneumothorax Infection: Represents a rapidly growing critical care segment, driven by increasing emergency hospital admissions and urgent respiratory intervention requirements.

Others: Represents a moderate segment, supported by expanding diagnosis of iatrogenic and procedure-related pneumothorax conditions.

➥ By End-User

Hospitals: Represents the dominant segment, driven by availability of advanced thoracic surgery infrastructure, emergency respiratory care units, and high patient admission rates.

Clinics: Represents a significant segment, supported by increasing outpatient respiratory consultations and follow-up treatment services.

Ambulatory Surgery Centers: Represents a growing segment, fueled by rising adoption of minimally invasive thoracic procedures and same-day surgical interventions.

Others: Represents a moderate segment, driven by expanding utilization in rehabilitation centers, specialty pulmonary care facilities, and home healthcare settings.

➥ By Distribution Channel

Hospital Pharmacies: Represents the dominant segment, driven by high inpatient medication usage and extensive administration of emergency respiratory treatments within hospital settings.

Retail Pharmacies: Represents a significant segment, supported by widespread accessibility of supportive medications and outpatient prescription therapies.

Online Pharmacies: Represents a rapidly growing segment, fueled by increasing digital healthcare adoption and growing preference for convenient access to respiratory medications.

Others: Represents a moderate segment, driven by expanding distribution through specialty pharmacies and integrated healthcare service providers.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.